Zomedica Corp (ZOM) gains 1.45% for July 21

Equities Staff  |

Zomedica Corp (NYSE: ZOM) shares gained 1.45%, or $0.0094 per share, to close Wednesday at $0.66. After opening the day at $0.66, shares of Zomedica fluctuated between $0.68 and $0.64. 19,329,575 shares traded hands a decrease from their 30 day average of 25,202,704. Wednesday's activity brought Zomedica’s market cap to $643,499,284.

About Zomedica Corp

Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.

Visit Zomedica Corp’s profile for more information.

About The New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on Zomedica Corp and to follow the company’s latest updates, you can visit the company’s profile page here: Zomedica Corp’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content